GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
- Conditions
- Acute Myeloid LeukemiaHematologic Malignancy
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT03135028
- Locations
- 🇯🇵
University of Fukui Hospital, Fukui, Japan
🇯🇵Tokai University Hospital, Kanagawa, Japan
🇯🇵Tohoku University Hospital, Miyagi, Japan
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT03134222
- Locations
- 🇨🇦
K.Papp Clinical Research, Waterloo, Canada
🇨🇦Dermatology Ottawa Research Centre, Ottawa, Canada
🇺🇸St. Jude Hospital Yorba Linda DBA Dr. Joseph Heritage Healthcare, Fullerton, California, United States
Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT03118843
- Locations
- 🇺🇸
Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸Stanford Hospital and Clinics, Palo Alto, California, United States
🇺🇸Kaiser Permanente, San Diego, California, United States
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 567
- Registration Number
- NCT03110380
- Locations
- 🇵🇷
Instituto de Investigacion Cientifica del Sur, Ponce, Puerto Rico
🇵🇷Proyecto ACTU, San Juan, Puerto Rico
🇺🇸Mills Clinical Research, Los Angeles, California, United States
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
- Conditions
- Sjogren's Syndrome
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 152
- Registration Number
- NCT03100942
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Center for Rheumatology Immunology and Arthritis, Fort Lauderdale, Florida, United States
🇺🇸IRIS Research and Development, LLC, Plantation, Florida, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
- Conditions
- Fistulizing Crohn's Disease
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT03077412
- Locations
- 🇺🇸
Gastro One, Germantown, Tennessee, United States
🇺🇸DHAT Research Institute, Garland, Texas, United States
🇺🇸Texas Digestive Disease Consultants, Southlake, Texas, United States
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 130
- Registration Number
- NCT03074331
- Locations
- 🇮🇳
Institute of Digestive and Liver Disease, Guwahati, India
🇮🇳YRG Care, Chennai, Tamil Nadu, India
🇮🇳All India Institute of Medical Sciences, Delhi, New Delhi, India
Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT03060447
- Locations
- 🇺🇸
Peter Shalit, MD, Seattle, Washington, United States
🇺🇸Central Texas Clinical Research, Austin, Texas, United States
🇺🇸Zuckerberg San Francisco General, San Francisco, California, United States
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: SELDrug: Placebo to match SEL 18 mgDrug: Placebo to match SEL 6 mg
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 883
- Registration Number
- NCT03053063
- Locations
- 🇺🇸
Ruane Clinical Research Group, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: SELDrug: Placebo to match SEL 6 mgDrug: Placebo to match SEL 18 mg
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 808
- Registration Number
- NCT03053050
- Locations
- 🇧🇷
Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, São Paulo, Brazil
🇺🇸Baptist Medical Center, Little Rock, Arkansas, United States
🇺🇸Southern California Liver Centers, Coronado, California, United States